Avita Medical Income Taxes 2011-2024 | RCEL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Avita Medical income taxes from 2011 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Avita Medical income taxes from 2011 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$79.7B
Takeda Pharmaceutical (TAK)	$42.4B
Sandoz Group AG (SDZNY)	$19.3B
Merck (MKKGY)	$18.8B
Astellas Pharma (ALPMY)	$18.3B
United Therapeutics (UTHR)	$16.4B
Summit Therapeutics (SMMT)	$13.6B
Neurocrine Biosciences (NBIX)	$12.7B
Shionogi (SGIOY)	$11.8B
Catalent (CTLT)	$10.8B
Jazz Pharmaceuticals (JAZZ)	$7.6B
Madrigal Pharmaceuticals (MDGL)	$7.2B
Orion OYJ (ORINY)	$6.7B
Corcept Therapeutics (CORT)	$5.9B
Ionis Pharmaceuticals (IONS)	$5.4B
Crinetics Pharmaceuticals (CRNX)	$5.3B
PTC Therapeutics (PTCT)	$3.3B
Dyne Therapeutics (DYN)	$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.5B
Soleno Therapeutics (SLNO)	$2.4B
Arrowhead Pharmaceuticals (ARWR)	$2.3B
Centessa Pharmaceuticals (CNTA)	$2.1B
Evotec AG (EVO)	$1.9B
NewAmsterdam Pharma (NAMS)	$1.9B
Xencor (XNCR)	$1.7B
Recursion Pharmaceuticals (RXRX)	$1.6B
Harrow (HROW)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Cassava Sciences (SAVA)	$1.5B